Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8280
Reference
Drug alert 43/2024
Name
Drug Alert Class 4 Drug Alert 43 2024 – Class 4 medicines defect information – caution in use – Sandoz Ltd – Risperidone 1mg, 2mg and 3mg
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Department
Keywords
NHS
Scotland
Drugs
Safety
Risks
Pharmaceutical Industry
Medicines Recall
Description
Sandoz Ltd. has informed the MHRA that there is missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for Risperidone 1mg, 2mg and 3mg and Tablets. The PIL and SmPC does not include the Adverse event of Stevens Johnson’s syndrome and toxic epidermal necrolysis in section 4.8 Adverse drug reactions for the MedDRA System Organ Class ‘Skin and subcutaneous tissue disorders’.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2024-09-26 08:37:00
Click to go back to homepage